Parsabiv Could Allow Amgen To Maintain Control Of Calcimimetics Market
Executive Summary
Amgen's oral calcimimetic Sensipar faces generic competition in 2018, but the new intravenuous Parsabiv has advantages that could make it the more popular alternative.